APRIL/TNFSF13 Antibody Blocking Peptide

• Reactivity: Hu
• Applications: AC
• Concentration: 0.2 mg/ml

APRIL/TNFSF13 Antibody Blocking Peptide Summary

• Description: A blocking peptide containing 15 amino acids near the extracellular domain of human APRIL.

  Source: Synthetic

  (Accession #: NP_003799)

• Source: Synthetic
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: TNFSF13
• Purity: N/A

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NBP1-76767.
  
  For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin.
• Preservative: 0.02% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: N/A

Alternate Names for APRIL/TNFSF13 Antibody Blocking Peptide

• A proliferation-inducing ligand
• APRIL
• APRILFLJ57090
• CD256 antigen
• CD256
• TALL2
• TALL-2
• TNF- and APOL-related leukocyte expressed ligand 2
• TNF-related death ligand 1
• TNFSF13
• TRDL1
• TRDL-1
• tumor necrosis factor (ligand) superfamily, member 13
• tumor necrosis factor ligand superfamily member 13
• tumor necrosis factor-like protein ZTNF2
• tumor necrosis factor-related death ligand-1
• ZTNF2

Background

TNFSF13 is a proliferation-inducing ligand (APRIL), also designated TNFSF13, is a Type II membrane protein that shares characteristics with other members of the tumor necrosis factor (TNF) cytokine family. APRIL is expressed in high levels in transformed cell lines and in human colon, thyroid, and lymphoid tumor tissues. APRIL is critically involved in the regulation of infections, inflammation, autoimmune diseases, and tissue homeostasis. APRIL is implicated in the regulation of tumor cell growth. The C-terminal extracellular domain has b jelly roll topography and is important in ligand trimerization. The binding of the ligand to its respective receptor induces oligomerization, initiating downstream signaling events. Intrinsic to oligomerization is the formation of the receptor binding site at the junction between neighboring subunits, creating a multivalent ligand.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: TNFSF13